434 related articles for article (PubMed ID: 33414764)
1. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.
Henriksson E; Andersen B
Front Endocrinol (Lausanne); 2020; 11():601349. PubMed ID: 33414764
[TBL] [Abstract][Full Text] [Related]
2. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
[TBL] [Abstract][Full Text] [Related]
3. TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk.
Bhat N; Esteghamat F; Chaube BK; Gunawardhana K; Mani M; Thames C; Jain D; Ginsberg HN; Fernandes-Hernando C; Mani A
FASEB J; 2022 Mar; 36(3):e22185. PubMed ID: 35133032
[TBL] [Abstract][Full Text] [Related]
4. FGF19 and FGF21: In NASH we trust.
Talukdar S; Kharitonenkov A
Mol Metab; 2021 Apr; 46():101152. PubMed ID: 33383173
[TBL] [Abstract][Full Text] [Related]
5. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho.
Aaldijk AS; Verzijl CRC; Jonker JW; Struik D
Front Endocrinol (Lausanne); 2023; 14():1150222. PubMed ID: 37260446
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
[TBL] [Abstract][Full Text] [Related]
7. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.
Kurosu H; Choi M; Ogawa Y; Dickson AS; Goetz R; Eliseenkova AV; Mohammadi M; Rosenblatt KP; Kliewer SA; Kuro-O M
J Biol Chem; 2007 Sep; 282(37):26687-26695. PubMed ID: 17623664
[TBL] [Abstract][Full Text] [Related]
8. FGF19 subfamily members: FGF19 and FGF21.
Dolegowska K; Marchelek-Mysliwiec M; Nowosiad-Magda M; Slawinski M; Dolegowska B
J Physiol Biochem; 2019 Jun; 75(2):229-240. PubMed ID: 30927227
[TBL] [Abstract][Full Text] [Related]
9. FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia.
Lan T; Morgan DA; Rahmouni K; Sonoda J; Fu X; Burgess SC; Holland WL; Kliewer SA; Mangelsdorf DJ
Cell Metab; 2017 Nov; 26(5):709-718.e3. PubMed ID: 28988823
[TBL] [Abstract][Full Text] [Related]
10. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
Bao L; Yin J; Gao W; Wang Q; Yao W; Gao X
Br J Pharmacol; 2018 Aug; 175(16):3379-3393. PubMed ID: 29859019
[TBL] [Abstract][Full Text] [Related]
11. FGF21 acts as a negative regulator of bile acid synthesis.
Chen MM; Hale C; Stanislaus S; Xu J; Véniant MM
J Endocrinol; 2018 May; 237(2):139-152. PubMed ID: 29615519
[TBL] [Abstract][Full Text] [Related]
12. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.
Gallego-Escuredo JM; Gómez-Ambrosi J; Catalan V; Domingo P; Giralt M; Frühbeck G; Villarroya F
Int J Obes (Lond); 2015 Jan; 39(1):121-9. PubMed ID: 24813368
[TBL] [Abstract][Full Text] [Related]
13. Differential receptor selectivity of the FGF15/FGF19 orthologues determines distinct metabolic activities in
Hansen AMK; Vienberg SG; Lykkegaard K; Zhao X; Tingqing G; Han D; Zhang X; Thøgersen H; Sass-Ørum K; Tagmose T; Raun K; Andersen B
Biochem J; 2018 Sep; 475(18):2985-2996. PubMed ID: 30127091
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
Tucker B; Li H; Long X; Rye KA; Ong KL
Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
[TBL] [Abstract][Full Text] [Related]
15. Fundamentals of FGF19 & FGF21 action in vitro and in vivo.
Adams AC; Coskun T; Rovira AR; Schneider MA; Raches DW; Micanovic R; Bina HA; Dunbar JD; Kharitonenkov A
PLoS One; 2012; 7(5):e38438. PubMed ID: 22675463
[TBL] [Abstract][Full Text] [Related]
16. Dual actions of fibroblast growth factor 19 on lipid metabolism.
Wu X; Ge H; Baribault H; Gupte J; Weiszmann J; Lemon B; Gardner J; Fordstrom P; Tang J; Zhou M; Wang M; Li Y
J Lipid Res; 2013 Feb; 54(2):325-32. PubMed ID: 23204296
[TBL] [Abstract][Full Text] [Related]
17. Selective Regulation of FGF19 and FGF21 Expression by Cellular and Nutritional Stress.
Shimizu M; Morimoto H; Maruyama R; Inoue J; Sato R
J Nutr Sci Vitaminol (Tokyo); 2015; 61(2):154-60. PubMed ID: 26052146
[TBL] [Abstract][Full Text] [Related]
18. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism.
Cariello M; Piglionica M; Gadaleta RM; Moschetta A
Handb Exp Pharmacol; 2019; 256():73-93. PubMed ID: 31123830
[TBL] [Abstract][Full Text] [Related]
19. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.
Tanaka N; Takahashi S; Zhang Y; Krausz KW; Smith PB; Patterson AD; Gonzalez FJ
Biochim Biophys Acta; 2015 Jul; 1852(7):1242-52. PubMed ID: 25736301
[TBL] [Abstract][Full Text] [Related]
20. Relevant use of Klotho in FGF19 subfamily signaling system in vivo.
Tomiyama K; Maeda R; Urakawa I; Yamazaki Y; Tanaka T; Ito S; Nabeshima Y; Tomita T; Odori S; Hosoda K; Nakao K; Imura A; Nabeshima Y
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1666-71. PubMed ID: 20080590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
